Dr. Sharon Shacham has served on Acrivon's Board since October 2020. She has served as CEO of Regenimo Biosciences since September 2025 and co-founded and is Managing Director of the venture-capital firm E44 Ventures. She founded Karyopharm Therapeutics in 2008 and served in roles including Chief Scientific Officer and President, leading the scientific and clinical work behind selinexor (Xpovio), a first-in-class oral XPO1 inhibitor. Earlier she was Senior Vice President of Drug Development at Epix Pharmaceuticals. She currently serves as a director of Nasus Pharma. Dr. Shacham holds a B.S. in chemistry, a Ph.D. in biophysical chemistry and an M.B.A. from Tel Aviv University. She serves on Acrivon's Compensation Committee.